Valuation : Adimmune Corporation

Market Cap 7.46B 235M 203M 191M 174M 327M 22.34B 329M 2.26B 879M 11.37B 884M 865M 37.69B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 8.07B 255M 220M 207M 188M 354M 24.18B 356M 2.44B 951M 12.3B 956M 936M 40.78B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.19%
Yield 2024 *
-
Yield 2025 -
1 day-0.28%
Current month-0.28%
1 month+6.95%
3 months+2.91%
6 months-1.67%
Current year-6.60%
1 week 17.65
Extreme 17.65
18.2
1 month 16.45
Extreme 16.45
18.55
Current year 16.4
Extreme 16.4
21.5
1 year 16.4
Extreme 16.4
22.5
3 years 15.9
Extreme 15.9
36.6
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 19/06/2019
Director of Finance/CFO - 31/12/2020
Chief Tech/Sci/R&D Officer - 25/01/2022
Director TitleAgeSince
Director/Board Member - 19/06/2019
Director/Board Member - 14/08/2011
Director/Board Member - 28/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%0.00%-0.56%-46.69% 235M
+3.10%-1.17%+41.87%-0.94% 82.26B
+0.52%+0.46%-16.87%-35.47% 59.05B
+9.93%-2.87%+540.39%+37.06% 61.59B
+0.13%-4.10%-0.74%+34.87% 51.23B
+1.49%-2.50%+9.69%+163.06% 48.3B
-0.28%-2.14%+63.39%-19.14% 31.92B
+1.45%-3.63%+47.75%+93.24% 25.34B
-0.59%-8.01%-4.08%+192.75% 22.56B
+1.69%-2.60%+61.63%+116.78% 16.56B
Average +1.72%-2.33%+74.25%+53.55% 39.9B
Weighted average by Cap. +2.55%-2.66%+101.05%+44.60%

Financials

2024 2025
Net sales 1.56B 49.13M 42.38M 39.87M 36.32M 68.3M 4.66B 68.67M 471M 183M 2.37B 184M 180M 7.86B 1.4B 44.23M 38.15M 35.88M 32.69M 61.48M 4.2B 61.81M 424M 165M 2.14B 166M 162M 7.08B
Net income -243M -7.66M -6.61M -6.22M -5.66M -10.65M -727M -10.71M -73.48M -28.6M -370M -28.76M -28.14M -1.23B -240M -7.57M -6.53M -6.14M -5.6M -10.52M -718M -10.58M -72.61M -28.26M -365M -28.42M -27.8M -1.21B
Net Debt 140M 4.4M 3.8M 3.57M 3.26M 6.12M 418M 6.15M 42.24M 16.44M 213M 16.53M 16.18M 705M 612M 19.32M 16.67M 15.68M 14.28M 26.86M 1.83B 27M 185M 72.14M 933M 72.54M 70.97M 3.09B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
01/09/26 NT$17.70 -0.28% 491,110
31/08/26 NT$17.75 -0.84% 574,808
28/08/26 NT$17.90 0.00% 659,220
27/08/26 NT$17.90 -0.56% 898,737
26/08/26 NT$18.00 +1.69% 2,011,846
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock